Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone973-532-8000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.20 million
Profitability
Miscellaneous
Employees6
Next Earnings DateN/A
OptionableNot Optionable
Emisphere Technologies (OTCMKTS:EMIS) Frequently Asked Questions
What is Emisphere Technologies' stock symbol?
Emisphere Technologies trades on the OTCMKTS under the ticker symbol "EMIS."
How were Emisphere Technologies' earnings last quarter?
Emisphere Technologies, Inc. (OTCMKTS:EMIS) posted its earnings results on Friday, May, 12th. The company reported $0.04 earnings per share (EPS) for the quarter. The business had revenue of $0.22 million for the quarter. View Emisphere Technologies' Earnings History.
Has Emisphere Technologies been receiving favorable news coverage?
News headlines about EMIS stock have been trending extremely negative recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Emisphere Technologies earned a news impact score of -4.7 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Emisphere Technologies.
Who are some of Emisphere Technologies' key competitors?
Some companies that are related to Emisphere Technologies include Global Blood Therapeutics (GBT), Arena Pharmaceuticals (ARNA), Amicus Therapeutics (FOLD), HUTCHISON CHINA/S (HCM), Arrowhead Pharmaceuticals (ARWR), Agios Pharmaceuticals (AGIO), Uniqure (QURE), The Medicines (MDCO), Reata Pharmaceuticals (RETA), PTC Therapeutics (PTCT), Xencor (XNCR), Myokardia (MYOK), Nabriva Therapeutics (NBRV), Emergent Biosolutions (EBS) and Ligand Pharmaceuticals (LGND).
What other stocks do shareholders of Emisphere Technologies own?
Who are Emisphere Technologies' key executives?
Emisphere Technologies' management team includes the folowing people:
- Mr. Alan L. Rubino, CEO, Pres & Director (Age 64)
- Mr. Alan V. Gallantar CPA, Interim Chief Financial Officer (Age 61)
How do I buy shares of Emisphere Technologies?
Shares of EMIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Emisphere Technologies' stock price today?
One share of EMIS stock can currently be purchased for approximately $9.35.
How big of a company is Emisphere Technologies?
What is Emisphere Technologies' official website?
How can I contact Emisphere Technologies?
Emisphere Technologies' mailing address is 4 BECKER FARM ROAD SUITE 103, ROSELAND NJ, 07068. The company can be reached via phone at 973-532-8000 or via email at [email protected]
MarketBeat Community Rating for Emisphere Technologies (OTCMKTS EMIS)
MarketBeat's community ratings are surveys of what our community members think about Emisphere Technologies and other stocks. Vote "Outperform" if you believe EMIS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EMIS will underperform the S&P 500 over the long term. You may vote once every thirty days.
